<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>EPANED- enalapril maleateÂ 
			Â </strong><br>Silvergate Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use EPANED safely and effectively. See full prescribing information for EPANED. <br><br>EPANEDâ„¢ (enalapril) for Oral Solution<br>Initial U.S. Approval: 1985</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue EPANED as soon as possible. (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>) </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<p class="Highlighta"> </p>
<p class="Highlighta">Indications and Usage (<a href="#i4i_indications_id_01605ee6-fc41-40d0-a935-ac5e0c71aad7">1</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 09/2014 </p>
<p class="Highlighta">Dosage and Administration (<a href="#i4i_dosage_admin_id_084e0ea9-95b4-4413-adf0-5b28c4da3057">2</a>)Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 09/2014 </p>
</div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: FETAL TOXICITY</h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning</span></span></h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue EPANED as soon as possible. (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>) </span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">EPANED is an angiotensin-converting enzyme inhibitor indicated for: </p>
<dl>
<dt>â€¢</dt>
<dd>treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. (<a href="#i4i_section_id_b9c0933a-d672-4568-91c6-12256185889d">1.1</a>)</dd>
<dt>â€¢</dt>
<dd>treatment of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_section_id_ee523ae7-4758-4dc9-afc3-c34f12b3f831">1.2</a>)</dd>
<dt>â€¢</dt>
<dd>treatment of asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span>, to decrease the rate of development of overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and reduce hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (<a href="#ID_78331324-de22-4a0d-a82b-531e6a8c6ec0">1.3</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </p>
<dl>
<dt>â€¢</dt>
<dd>Adult: recommended initial dose is 5 mg once daily. Maximum dose is 40 mg daily. (<a href="#i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9">2.1</a>)</dd>
<dt>â€¢</dt>
<dd>Pediatrics: recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. (<a href="#i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9">2.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>: Initiate at 2.5 mg twice daily. Titrate up to 20 mg twice daily as tolerated. (<a href="#i4i_section_id_99be343a-63d2-4ae4-9c18-ddd573b05740">2.2</a>) </p>
<p class="Highlighta">Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span>: Initiate at 2.5Â mg twice daily. Titrate up to 10 mg twice daily. <a href="#ID_7525cf9c-15b4-4b0a-be9d-6e0818c9bd80">(2.3</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">EPANED Powder for Oral Solution contains 150 mg of enalapril maleate in a 150 mL bottle. Reconstitution with 150 mL of ORA-SWEET<span class="Sup">Â®</span> SF provided results in a 1 mg/mL EPANED oral solution. (<a href="#i4i_dosage_form_strength_id_aaa65a54-76fd-4de7-991f-9303dd6ad2f5">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> related to previous treatment with an ACEI. (<a href="#i4i_contraindications_id_058ceeae-c2e5-4e6b-84dd-eaeeac6cdb0c">4</a>)</dd>
<dt>â€¢</dt>
<dd>Hereditary or idiopathic <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>. (<a href="#i4i_contraindications_id_058ceeae-c2e5-4e6b-84dd-eaeeac6cdb0c">4</a>)</dd>
<dt>â€¢</dt>
<dd>Do not co-administer aliskiren in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. (<a href="#i4i_contraindications_id_058ceeae-c2e5-4e6b-84dd-eaeeac6cdb0c">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span>. (<a href="#i4i_section_id_915c8239-d335-46ef-8cbf-0ffac03ec367">5.2</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>: Assess renal function. (<a href="#i4i_section_id_441e7e1e-a067-49ce-9157-768c7aa666c7">5.5</a>)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span>. (<a href="#i4i_section_id_81669c2e-70d3-4cf8-bd50-4edf4861fc59">5.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<dl>
<dt>â€¢</dt>
<dd>The most common adverse reaction for patients treated for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (â‰¥3%) was <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (<a href="#i4i_section_id_64fd6960-d7f4-4b92-b488-fb7b9f6e96dc">6.1</a>).</dd>
<dt>â€¢</dt>
<dd>The most common adverse reactions for patients treated for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (&gt;6%) were <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (<a href="#i4i_section_id_64fd6960-d7f4-4b92-b488-fb7b9f6e96dc">6.1</a>)</dd>
</dl>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Silvergate Pharmaceuticals at 1-855-379-0383 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>In patients who are elderly, volume-depleted (as on diuretic therapy), or with compromised renal function, use with NSAIDs, including selective COX-2 inhibitors, may result in deterioration of renal function, including <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>. Monitor renal function periodically. (<a href="#i4i_section_id_96214c97-a1a6-4722-838c-12067717b025">7.1</a>)</dd>
<dt>â€¢</dt>
<dd>Dual inhibition of the renin-angiotensin system: Increased risk of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. (<a href="#i4i_section_id_a7d7c50e-cd2c-4c3e-9a36-5b674f6fb341">7.2</a>)</dd>
<dt>â€¢</dt>
<dd>Avoid potassium sparing agents in patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_section_id_d815c9b8-0387-4b97-838d-e28a461d10a4">7.3</a>) </dd>
<dt>â€¢</dt>
<dd>Monitor serum lithium levels frequently. (<a href="#i4i_section_id_a83f013c-a1eb-4746-aadb-a5f87a39d983">7.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>EPANED is not recommended in neonates and in pediatric patients with glomerular filtration rate &lt;30 mL/min/1.73m<span class="Sup">2</span>. (<a href="#i4i_pediatric_use_id_998da307-0119-43f9-8fc7-1246c78ec387">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: FETAL TOXICITY</a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="XmChange">1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="XmChange">1.3 Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></a></h2>
<h2><a href="#section-2.2" class="toc"><span class="XmChange">2.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></a></h2>
<h2><a href="#section-2.3" class="toc"><span class="XmChange">2.3 Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span></a></h2>
<h2><a href="#section-2.4" class="toc"><span class="XmChange">2.4 Preparation of EPANED (for 150 mL, 1 mg/mL enalapril solution)</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Fetal Toxicity</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Other Adverse Reactions from Clinical Studies or Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Non-Steroidal Anti-Inflammatory Agents (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Dual Blockade of the Renin-Angiotensin System (RAS)</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Agents Increasing Serum Potassium</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Lithium</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Gold</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, Mortality Trials</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_id_b1cc2b3d-4ac5-4e86-a4d7-89d11365f476"></a><a name="section-1"></a><p></p>
<h1>WARNING: FETAL TOXICITY</h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">When pregnancy is detected, discontinue EPANED<span class="Sup">Â®</span> as soon as possible. <span class="Italics">[See Warnings and Precautions (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>)]</span></span></dd>
<dt>â€¢</dt>
<dd><span class="Bold">Drugs that act directly on the renin-angiotensin system can cause injury and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus. <span class="Italics">[See Warnings and Precautions (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>)]</span></span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_01605ee6-fc41-40d0-a935-ac5e0c71aad7"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b9c0933a-d672-4568-91c6-12256185889d"></a><a name="section-1.1"></a><p></p>
<h2>1.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First">EPANED is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, to lower blood pressure in adults and children older than one month.</p>
<p> Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">strokes</span> and <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarctions</span>. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. </p>
<p>Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Programâ€™s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).</p>
<p>Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, but reductions in <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and cardiovascular mortality also have been seen regularly.</p>
<p>Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (for example, patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.</p>
<p>Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g.,Â on angina, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, or diabetic kidney disease). These considerations may guide selection of therapy.</p>
<p>EPANED is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of EPANED and thiazides are approximately additive.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ee523ae7-4758-4dc9-afc3-c34f12b3f831"></a><a name="section-1.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">EPANED is indicated for the treatment of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, usually in combination with diuretics and digitalis. In these patients, EPANED increases survival and decreases the frequency of hospitalization.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_78331324-de22-4a0d-a82b-531e6a8c6ec0"></a><a name="section-1.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.3 Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">In clinically stable asymptomatic patients with <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> (<span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤35 percent), EPANED decreases the rate of development of overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and decreases the incidence of hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_084e0ea9-95b4-4413-adf0-5b28c4da3057"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9"></a><a name="section-2.1"></a><p></p>
<h2>2.1 <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></h2>
<p class="First"><span class="Bold"><span class="Underline">Adults</span></span>: The recommended initial dose in adults is 5 mg once a day. Titrate upward to maximum of 40 mg daily as needed to help achieve blood pressure goals. The dose may be divided and administered twice daily if the antihypertensive effect diminishes at the end of the dosing interval. </p>
<p><span class="Italics">Use with diuretics: </span>If additional blood pressure reduction is needed, EPANED may be administered with a low dose of diuretic. The recommended initial dose in patients taking diuretics is 2.5 mg daily. </p>
<p><span class="Italics">Dosage Adjustment for <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> See table below. The dosage may be titrated upward as needed to a maximum of 40 mg daily.</p>
<table width="100%">
<col width="34%">
<col width="34%">
<col width="32%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd><span class="Italics">[See Warnings and Precautions (<a href="#i4i_section_id_915c8239-d335-46ef-8cbf-0ffac03ec367">5.2</a>)].</span></dd>
<dt><a name="footnote-2" href="#footnote-reference-2">â€ </a></dt>
<dd>Dosage on nondialysis days should be adjusted depending on the blood pressure response.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Toprule" align="center"><p class="First"><span class="Bold">Renal Status</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Creatinine-Clearance</span><br><span class="Bold">mL/min</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Initial Dose</span><br><span class="Bold">mg/day</span></p></td>
</tr>
<tr>
<td><p class="First">Normal or Mild Impairment of Renal Function</p></td>
<td align="center"><p class="First">Â Â Â Â Â Â Â Â Â Â &gt;30Â mL/minÂ Â Â Â Â Â Â Â Â Â </p></td>
<td align="center"><p class="First">5 mg</p></td>
</tr>
<tr>
<td><p class="First">ModerateÂ toÂ SevereÂ ImpairmentÂ Â Â Â Â </p></td>
<td align="center"><p class="First">â‰¤30 mL/min</p></td>
<td align="center"><p class="First">2.5 mg</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Dialysis Patients<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
<td class="Botrule" align="center"><p class="First">â€“</p></td>
<td class="Botrule" align="center"><p class="First">Â Â Â Â Â 2.5Â mgÂ onÂ dialysisÂ days<a name="footnote-reference-2" href="#footnote-2" class="Sup">â€ </a>Â Â Â Â Â </p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline">Children &gt;1 month:</span></span> The usual recommended starting dose is 0.08 mg/kg (up to 5 mg) once daily. Dosage should be adjusted according to blood pressure response. Doses above 0.58 mg/kg (or in excess of 40 mg) have not been studied in pediatric patients <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_09d2d1c3-6224-408e-aecb-aec9d4d7d969">12.3</a>)]</span>.</p>
<p>EPANED is not recommended in neonates and in pediatric patients with glomerular filtration rate &lt;30 mL/min/1.73 m<span class="Sup">2</span>, as no data are available.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_99be343a-63d2-4ae4-9c18-ddd573b05740"></a><a name="section-2.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.2 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Generally, the recommended initial dose is 2.5 mg twice a day titrated up to a maximum of 20 mg twice a day, as tolerated. Doses are usually given in combination with diuretics and digitalis.  </span></p>
<p style="border-left:1px solid;"><span class="XmChange">In patients with <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span> (serum sodium less than 130 mEq/L) or serum creatinine greater than 1.6 mg/dL, the recommended initial dose is 2.5 mg once daily. </span></p>
<p style="border-left:1px solid;"><span class="XmChange">Diuretic dose may need to be adjusted to minimize <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. The appearance of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> after the initial dose of EPANED does not preclude subsequent careful dose titration with the drug, following effective management of the <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_7525cf9c-15b4-4b0a-be9d-6e0818c9bd80"></a><a name="section-2.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.3 Asymptomatic <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">Left Ventricular Dysfunction</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended initial dose is 2.5 mg twice a day titrated up to a maximum of 10 mg twice a day, as tolerated. Diuretic dose may need to be adjusted [see Dosage and Administration (<a href="#i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9">2.1</a>)].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_06c5fdb4-0b8b-4776-930e-197fba5c84bc"></a><a name="section-2.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.4 Preparation of EPANED (for 150 mL, 1 mg/mL enalapril solution)</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">EPANED Powder for Oral Solution is a kit containing 1 bottle of enalapril powder and 1Â bottle of Ora-Sweet SF diluent to be added to the enalapril powder prior to dispensing to the patient.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Firmly tap the EPANED Powder for Oral Solution bottle on a hard surface 5 times. Add approximately one-half (75Â mL) of the Ora-Sweet SF diluent to the 150Â mL EPANED Powder for Oral Solution bottle. Replace the child-resistant cap. Shake well for 30Â seconds. Reopen. Add the remainder of the Ora-Sweet SF diluent to the EPANED Powder for Oral Solution bottle, replace the child-resistant cap and shake well for an additional 30Â seconds. Calculate 60 days from the date of reconstitution. Write this date as the discard date on the front of the label. Affix a â€œDo Not Use Afterâ€? or a â€œDiscard Afterâ€? label with the calculated date added to the reconstituted EPANED bottle.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_aaa65a54-76fd-4de7-991f-9303dd6ad2f5"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">EPANED Powder for Oral Solution is a kit that contains 150Â mg of enalapril maleate in a 150-mL bottle and Ora-Sweet SF diluent. Reconstitution with 150Â mL of the provided Ora-Sweet SF diluent results in a 1Â mg/mL EPANED oral solution.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_058ceeae-c2e5-4e6b-84dd-eaeeac6cdb0c"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">EPANED is contraindicated in patients with: </p>
<dl>
<dt>â€¢</dt>
<dd>a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> related to previous treatment with an angiotensin converting enzyme (ACE) inhibitor <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_915c8239-d335-46ef-8cbf-0ffac03ec367">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd>hereditary or idiopathic <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_915c8239-d335-46ef-8cbf-0ffac03ec367">5.2</a>)]</span>.</dd>
</dl>
<p>Do not co-administer aliskiren with EPANED in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_a7d7c50e-cd2c-4c3e-9a36-5b674f6fb341">7.2</a>)]</span>.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_f2d27aea-6333-427e-88e1-8716460be087"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Fetal Toxicity</h2>
<p class="First">Pregnancy Category D</p>
<p>Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Resulting <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. When pregnancy is detected, discontinue EPANED as soon as possible <span class="Italics">[see Use in Specific Populations (<a href="#i4i_pregnancy_id_143cb7d4-29b7-41b2-aab9-2531ab22511a">8.1</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_915c8239-d335-46ef-8cbf-0ffac03ec367"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First"><span class="Italics"><span class="Underline">Head and Neck <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis and/or larynx, including some fatal reactions, have occurred in patients treated with angiotensin converting enzyme inhibitors, including EPANED, at any time during treatment. Patients with involvement of the tongue, glottis or larynx are likely to experience airway obstruction, especially those with a history of airway surgery. EPANED should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has occurred.</p>
<p>Patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> unrelated to ACE inhibitor therapy may be at increased risk of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> while receiving an ACE inhibitor <span class="Italics">[see Contraindications (<a href="#i4i_contraindications_id_058ceeae-c2e5-4e6b-84dd-eaeeac6cdb0c">4</a>)]</span>. ACE inhibitors have been associated with a higher rate of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> in black than in non-black patients. </p>
<p><span class="Italics"><span class="Underline">Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></span></p>
<p>Intestinal <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> has occurred in patients treated with ACE inhibitors. These patients presented with <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> (with or without <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>); in some cases there was no prior history of facial <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> and C-1 esterase levels were normal. In some cases, the <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> was diagnosed by procedures including abdominal CT scan or ultrasound, or at surgery, and symptoms resolved after stopping the ACE inhibitor. </p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> during Desensitization</span></span></p>
<p>Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. </p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> during Dialysis</span></span></p>
<p>Sudden and potentially life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have occurred in some patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. In such patients, dialysis must be stopped immediately, and aggressive therapy for <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> must be initiated. Symptoms have not been relieved by antihistamines in these situations. In these patients, consideration should be given to using a different type of dialysis membrane or a different class of antihypertensive agent. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ec171974-cf52-4005-97a3-f88b36ffdd3f"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<p class="First">EPANED can cause symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, sometimes complicated by <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients at risk of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> include those with the following conditions or characteristics: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with systolic blood pressure below 100 mmHg, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>, cerebrovascular disease, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, high dose diuretic therapy, renal dialysis, or severe volume and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> of any etiology. </p>
<p>In these patients, EPANED should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of EPANED and/or diuretic is increased. </p>
<p>Symptomatic <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is also possible in patients with severe <span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">aortic stenosis</span> or <span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">hypertrophic cardiomyopathy</span>.</p>
<p><span class="Italics">Surgery/Anesthesia</span></p>
<p>In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, EPANED may block angiotensin II formation secondary to compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is considered to be through this mechanism, it can be corrected by volume expansion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0ffbf372-d85b-4d9f-a1aa-e451cef8a66f"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></h2>
<p class="First">Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and (sometimes) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_441e7e1e-a067-49ce-9157-768c7aa666c7"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></h2>
<p class="First">Monitor renal function in patients treated with EPANED. Changes in renal function including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> can be caused by drugs that inhibit the renin-angiotensin system. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>, <span class="product-label-link" type="condition" conceptid="196991" conceptname="Chronic renal impairment">chronic kidney disease</span>, severe <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, post-<span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>) may be at particular risk of developing <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> on EPANED. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on EPANED <span class="Italics">[see Adverse Reactions (<a href="#i4i_section_id_dc23597e-b654-4e97-8364-9f1a6804cb68">6.2</a>), Drug Interactions (<a href="#i4i_section_id_a7d7c50e-cd2c-4c3e-9a36-5b674f6fb341">7.2</a>, <a href="#i4i_section_id_d815c9b8-0387-4b97-838d-e28a461d10a4">7.3</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_81669c2e-70d3-4cf8-bd50-4edf4861fc59"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></h2>
<p class="First">Serum potassium should be monitored in patients receiving EPANED. Drugs that inhibit the renin angiotensin system can cause <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing diuretics, potassium supplements and/or potassium-containing salt substitutes <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_d815c9b8-0387-4b97-838d-e28a461d10a4">7.3</a>)].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_bffb32e5-722e-47d2-902c-6d17256082bb"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following adverse reactions are described elsewhere:</p>
<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_915c8239-d335-46ef-8cbf-0ffac03ec367">5.2</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ec171974-cf52-4005-97a3-f88b36ffdd3f">5.3</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic failure</span><span class="Italics"> [see Warnings and Precautions (<a href="#i4i_section_id_0ffbf372-d85b-4d9f-a1aa-e451cef8a66f">5.4</a>)]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_441e7e1e-a067-49ce-9157-768c7aa666c7">5.5</a>)] </span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_64fd6960-d7f4-4b92-b488-fb7b9f6e96dc"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>Enalapril has been evaluated for safety in more than 10,000 patients, including over 1,000Â patients treated for one year or more. </p>
<p>In clinical trials, discontinuation of therapy for clinical adverse experiences was required in 3.3% of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and in 5.7% of patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></span></p>
<p>Adverse reactions (where rate on enalapril exceeds the rate on placebo by at least 0.2%) occurring in greater than 1% of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> treated with enalapril in controlled clinical trials are shown below. In patients treated with enalapril, the maximum duration of therapy was three years; in placebo treated patients, the maximum duration of therapy was 12Â weeks.</p>
<a name="_RefIDFEA7598F047946E2ACA98725B12F0A59"></a><table width="100%">
<caption><span>Adverse Reactions Occurring in Greater Than 1% of Patients With <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </span></caption>
<col width="34%">
<col width="40%">
<col width="26%">
<tbody class="Headless">
<tr class="First">
<td class="Toprule"></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Â Â Â Â Â EnalaprilÂ MaleateÂ TabletsÂ Â Â Â Â </span><br><span class="Bold">(n = 2314)</span><br><span class="Bold">Incidence</span><br><span class="Bold">(discontinuation)</span></p></td>
<td class="Toprule" align="center"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">(n = 230)</span><br><span class="Bold">Â Â Â Â Â IncidenceÂ Â Â Â Â </span></p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Body As A Whole</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td align="center"><p class="First">3.0 (&lt;0.1)</p></td>
<td align="center"><p class="First">2.6</p></td>
</tr>
<tr>
<td><p class="First">Â Â OrthostaticÂ EffectsÂ Â Â Â Â Â Â Â Â Â </p></td>
<td align="center"><p class="First">1.2 (&lt;0.1)</p></td>
<td align="center"><p class="First">0.0</p></td>
</tr>
<tr>
<td><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></p></td>
<td align="center"><p class="First">1.1 (0.1)</p></td>
<td align="center"><p class="First">0.9</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Respiratory</span></p></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td align="center"><p class="First">1.3 (0.1)</p></td>
<td align="center"><p class="First">0.9</p></td>
</tr>
<tr>
<td><p class="First"><span class="Italics">Skin</span></p></td>
<td></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Â Â <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></p></td>
<td class="Botrule" align="center"><p class="First">1.4 (0.4)</p></td>
<td class="Botrule" align="center"><p class="First">0.4</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span></span></p>
<p>Adverse reactions seen in clinical trials of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> were similar to those seen in clinical trials for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. In patients treated for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, there was an increased incidence of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> 6.7 percent versus 0.6 percent in placebo and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> 7.9 percent versus 0.6 percent in placebo.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dc23597e-b654-4e97-8364-9f1a6804cb68"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Other Adverse Reactions from Clinical Studies or Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been reported in clinical studies or postmarketing experience with enalapril. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Other serious clinical adverse experiences occurring since the drug was marketed or adverse experiences occurring in 0.5 to 1.0% of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> in clinical trials are listed below and, within each category, are in order of decreasing severity.</p>
<p><span class="Italics">Cardiovascular:</span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, possibly secondary to excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in high risk patients <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ec171974-cf52-4005-97a3-f88b36ffdd3f">5.3</a>)]</span>; <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>; <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>; rhythm disturbances, including <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>; Raynaud's phenomenon.</p>
<p><span class="Italics">Digestive:</span> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Italics">Hematologic:</span> Rare cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
<p><span class="Italics">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>.</p>
<p><span class="Italics">Nervous/Psychiatric:</span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>), dream abnormality.</p>
<p><span class="Italics">Respiratory:</span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> and <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, pulmonary infiltrates, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Italics">Skin:</span> <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Italics">Special Senses:</span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>, <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">anosmia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, tearing.</p>
<p><span class="Italics">Urogenital:</span> <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">Flank pain</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
<p><span class="Italics">Miscellaneous:</span> A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>/<span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4157025" conceptname="Serositis">serositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, dermatologic manifestations.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_35158972-200c-46af-9b90-1f891a31f7ff"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_96214c97-a1a6-4722-838c-12067717b025"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Non-Steroidal Anti-Inflammatory Agents (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)</h2>
<p class="First">In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>. These effects are usually reversible. Monitor renal function periodically in patients receiving enalapril and NSAID therapy.</p>
<p>In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study, there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a7d7c50e-cd2c-4c3e-9a36-5b674f6fb341"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Dual Blockade of the Renin-Angiotensin System (RAS)</h2>
<p class="First">Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, and changes in renal function (including <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span>) compared to monotherapy. In most patients no benefit has been associated with using two RAS inhibitors concomitantly. In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function and electrolytes in patients on EPANED and other agents that affect the RAS.</p>
<p>Do not co-administer aliskiren with EPANED in patients with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>. Avoid use of aliskiren with EPANED in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (GFR &lt;60 mL/min).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d815c9b8-0387-4b97-838d-e28a461d10a4"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Agents Increasing Serum Potassium</h2>
<p class="First">EPANED attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a83f013c-a1eb-4746-aadb-a5f87a39d983"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Lithium</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> has been reported in patients receiving enalapril and lithium concomitantly which was generally reversible. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3471b681-e4a9-4e7a-af3f-396dc5283790"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Gold</h2>
<p class="First">Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including enalapril.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_28cfc4b2-478f-40f3-aa66-54e1c87d3beb"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_143cb7d4-29b7-41b2-aab9-2531ab22511a"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Fetal Toxicity</span><br><span class="Bold">Pregnancy Category D <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_cb7a514f-d721-42ba-9601-e513e4d6d3f8">5.1</a>)].</span></span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_6ad66f6e-5a2d-474c-a492-39d2a6c23d3e"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue EPANED, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_998da307-0119-43f9-8fc7-1246c78ec387"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><span class="Italics">Neonates with a history of in utero exposure to enalapril maleate:</span></p>
<p>If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, direct attention toward support of blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.</p>
<p><span class="Italics">Pediatric Patients 1 month to 16 years of age</span></p>
<p>Enalapril lowers blood pressure in hypertensive pediatric patients age 1 month to 16 years. Use of enalapril in these age groups is supported by evidence from adequate and well-controlled studies of enalapril in pediatric and adult patients as well as by published literature in pediatric patients <span class="Italics">[see Clinical Pharmacology (<a href="#i4i_pharmacokinetics_id_09d2d1c3-6224-408e-aecb-aec9d4d7d969">12.3</a>) and Dosage and Administration (<a href="#i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9">2.1</a>)]</span>.</p>
<p>EPANED is not recommended in neonates and in pediatric patients with glomerular filtration rate &lt;30 mL/min/1.73 m<span class="Sup">2</span>, as no data are available.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_636bc14a-a783-413c-97da-f269f9ad4c90"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Limited data are available in regard to overdosage in humans.</p>
<p>Single oral doses of enalapril above 1,000 mg/kg and â‰¥1,775 mg/kg were associated with lethality in mice and rats, respectively.</p>
<p>The most likely manifestation of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, for which the usual treatment would be intravenous infusion of normal saline solution.</p>
<p>Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis<span class="Italics">.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_ef9133c0-e047-4c45-9055-a5964311e3c1"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">EPANED (Enalapril Maleate) Powder for Oral Solution is the maleate salt of enalapril, the ethyl ester of a long-acting angiotensin-converting enzyme inhibitor, enalaprilat. Enalapril maleate is chemically described as (S)-1-[N-[1-(ethoxycarbonyl)-3-phenylpropyl]-L-alanyl]-L-proline, (Z)-2-butenedioate salt (1:1). Its empirical formula is C<span class="Sub">20</span>H<span class="Sub">28</span>N<span class="Sub">2</span>O<span class="Sub">5</span>â€¢C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span>, and its structural formula is:</p>
<div class="Figure">
<a name="id886"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94c9a9d6-957f-4667-8f09-509e99bac777&amp;name=image-01.jpg">
</div>
<p>Enalapril maleate is a white to off-white, crystalline powder with a molecular weight of 492.52. It is sparingly soluble in water, soluble in ethanol, and freely soluble in methanol.</p>
<p>Enalapril is a pro-drug; following oral administration, it is bioactivated by hydrolysis of the ethyl ester to enalaprilat, which is the active angiotensin-converting enzyme inhibitor.</p>
<p>EPANED Powder for Oral Solution is a kit consisting of 1 bottle containing a dry powder blend of enalapril maleate, USP, mannitol, and colloidal silicon dioxide and 1 bottle of Ora-Sweet SF diluent for reconstitution resulting in a 1 mg/mL EPANED oral solution. The Ora-Sweet SF diluent contains: purified water, glycerin, sorbitol, sodium saccharin, xanthan gum, and flavoring. Buffered with citric acid and sodium citrate. Preserved with methylparaben (0.03%), propylparaben (0.008%), and potassium sorbate (0.1%).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_b746ed40-8314-45e5-84f8-a15b31dd1498"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_1ba44923-4219-4be8-b812-7e9098a3f7b0"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Enalapril, after hydrolysis to enalaprilat, inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of enalapril in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> appear to result primarily from suppression of the renin-angiotensin-aldosterone system. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive patients treated with enalapril maleate tablets alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2Â mEq/L were observed. In patients treated with enalapril maleate tablets plus a thiazide diuretic, there was essentially no change in serum potassium <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_81669c2e-70d3-4cf8-bd50-4edf4861fc59">5.6</a>)]</span>. Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.</p>
<p>ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of EPANED remains to be elucidated.</p>
<p>While the mechanism through which EPANED lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, enalapril is antihypertensive even in patients with low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. Although enalapril maleate tablets was antihypertensive in all races studied, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalapril monotherapy than non-black patients.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_5a139499-8e7e-4330-b036-cbd081f83016"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </span></span></p>
<p><span class="Italics">Adults</span></p>
<p>Administration of enalapril maleate tablets to patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> of severity ranging from mild to severe results in a reduction of both supine and standing blood pressure, usually with no orthostatic component. Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> is therefore infrequent, although it might be anticipated in volume-depleted patients <span class="Italics">[see Warnings and Precautions (<a href="#i4i_section_id_ec171974-cf52-4005-97a3-f88b36ffdd3f">5.3</a>)]</span>.</p>
<p>In most patients studied, after oral administration of a single dose of enalapril, onset of antihypertensive activity was seen at one hour with peak reduction of blood pressure achieved by four to six hours.</p>
<p>At recommended doses, antihypertensive effects have been maintained for at least 24 hours. In some patients the effects may diminish toward the end of the dosing interval <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9">2.1</a>)]</span>.</p>
<p>In some patients achievement of optimal blood pressure reduction may require several weeks of therapy.</p>
<p>The antihypertensive effects of enalapril have continued during long-term therapy. Abrupt withdrawal of enalapril has not been associated with a rapid increase in blood pressure.</p>
<p>In hemodynamic studies in patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span>, blood pressure reduction was accompanied by a reduction in peripheral arterial resistance with an increase in <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and little or no change in heart rate. Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>.</p>
<p>When given together with thiazide-type diuretics, the blood pressure lowering effects of enalapril maleate are approximately additive.</p>
<p>In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate tablets. In this study, there was no evidence of a blunting of the antihypertensive action of enalapril <span class="Italics">[see Drug Interactions (<a href="#i4i_section_id_96214c97-a1a6-4722-838c-12067717b025">7.1</a>)]</span>.</p>
<p><span class="Italics">Pediatric Patients</span></p>
<p>In a clinical study involving 110 hypertensive pediatric patients 6 to 16 years of age, patients who weighed &lt;50 kg received either 0.625, 2.5, or 20Â mg of enalapril daily and patients who weighed â‰¥50 kg received either 1.25, 5, or 40 mg of enalapril daily.  Enalapril administration once daily lowered trough blood pressure in a dose-dependent manner.  The dose-dependent antihypertensive efficacy of enalapril was consistent across all subgroups (age, Tanner stage, gender, race).  However, the lowest doses studied, 0.625 mg and 1.25 mg, corresponding to an average of 0.02Â mg/kg once daily, did not appear to offer consistent antihypertensive efficacy.  In this study, enalapril maleate was generally well tolerated.</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span> </span></span></p>
<p>In trials in patients treated with digitalis and diuretics, treatment with enalapril resulted in decreased systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>, blood pressure, pulmonary capillary wedge pressure and heart size, and increased <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and exercise tolerance. Heart rate was unchanged or slightly reduced, and mean <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> was unchanged or increased. There was a beneficial effect on severity of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> as measured by the New York Heart Association (NYHA) classification and on symptoms of <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. Hemodynamic effects were observed after the first dose, and appeared to be maintained in uncontrolled studies lasting as long as four months. Effects on exercise tolerance, heart size, and severity and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> were observed in placebo-controlled studies lasting from eight weeks to over one year.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_09d2d1c3-6224-408e-aecb-aec9d4d7d969"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetics of EPANED Oral Solution were shown to be similar to that of Vasotec<span class="Sup">Â®</span> tablets under fasted conditions. A high-fat meal reduced the C<span class="Sub">max</span> of enalapril and enalaprilat by 46% and 36%, respectively. The exposure, as measured by AUC, to enalaprilat was reduced by 23%. The time to peak concentrations (C<span class="Sub">max</span>) was delayed by 20 minutes for enalapril and 62 minutes for enalaprilat. The trough plasma concentrations of enalapril (from 6 to 12 hours) and enalaprilat (from 16 to 36 hours) are similar between fasted and fed administrations.</p>
<p><span class="Italics">Adults</span></p>
<p>Following oral administration of enalapril maleate tablets, peak serum concentrations of enalapril occur within about one hour. Based on urinary recovery, the extent of absorption of enalapril is approximately 60%. Enalapril absorption is not influenced by the presence of food in the gastrointestinal tract. Following absorption, enalapril is hydrolyzed to enalaprilat, which is a more potent angiotensin-converting enzyme inhibitor than enalapril; enalaprilat is poorly absorbed when administered orally. Peak serum concentrations of enalaprilat occur three to fourÂ hours after an oral dose of enalapril maleate. Excretion of enalapril is primarily renal. </p>
<p>Approximately 94% of the dose is recovered in the urine and feces as enalaprilat or enalapril. The principal components in urine are enalaprilat, accounting for about 40% of the dose, and intact enalapril. There is no evidence of metabolites of enalapril, other than enalaprilat.</p>
<p>The serum concentration profile of enalaprilat exhibits a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-lifeÂ  for accumulation of enalaprilat following multiple doses of enalapril maleate is 11 hours.</p>
<p>The disposition of enalapril and enalaprilat in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With glomerular filtration rate â‰¤30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases, and time to steady state may be delayed. The effective half-life of enalaprilat following multiple doses of enalapril maleate is prolonged at this level of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> <span class="Italics">[see Dosage and Administration (<a href="#i4i_section_id_971eafdf-717e-40da-8b65-6ac128f612d9">2.1</a>)]</span>. Enalaprilat is dialyzable at the rate of 62Â mL/min.</p>
<p><span class="Italics">Pediatric Patients </span></p>
<p>A multiple dose pharmacokinetic study was conducted in 40 hypertensive male and female pediatric patients aged 2 months to â‰¤16 years following daily oral administration of 0.07 to 0.14Â mg/kg enalapril maleate. At steady state, the mean effective half-life for accumulation of enalaprilat was 14 hours and the mean urinary recovery of total enalapril and enalaprilat in 24Â hours was 68% of the administered dose. Conversion of enalapril to enalaprilat was in the range of 63-76%. The overall results of this study indicate that the pharmacokinetics of enalapril in hypertensive children aged 2 months to â‰¤16 years are consistent across the studied age groups and consistent with pharmacokinetic historic data in healthy adults.</p>
<p>In the above pediatric study, enalapril maleate was given as tablets and for those children and infants who were unable to swallow tablets or who required a lower dose than is available in tablet form, enalapril was administered in a suspension formulation.</p>
<p>Studies in dogs indicate that enalapril crosses the blood-brain barrier poorly, if at all; enalaprilat does not enter the brain. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk of lactating rats contains radioactivity following administration of <span class="Sup">14</span>C-enalapril maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_553be561-da97-4fc5-86ab-b505c05d0361"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_e416afe7-b3b1-4eb8-8bd6-c21b27970467"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to male and female rats at doses up to 90Â mg/kg/day or for 94 weeks to male and female mice at doses up to 90Â and 180 mg/kg/day, respectively. These doses are 26 times (in rats and female mice) and 13 times (in male mice) the maximum recommended human daily dose (MRHDD) when compared on a body surface area basis.</p>
<p>Neither enalapril maleate nor the active diacid was mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril was also negative in the following genotoxicity studies: rec-assay, reverse mutation assay with <span class="Italics">E. coli</span>, sister chromatid exchange with cultured mammalian cells, and the micronucleus test with mice, as well as in an inÂ vivo cytogenic study using mouse bone marrow.</p>
<p>There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril (26 times the MRHDD when compared on a body surface area basis).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_cef7cd18-2908-4ab7-9b89-fb80a3b2420b"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2df2f8a8-bf27-4cc8-8870-24f940869f94"></a><a name="section-13.1"></a><p></p>
<h2>14.1 <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart Failure</span>, Mortality Trials</h2>
<p class="First">In a multicenter, placebo-controlled clinical trial, 2,569 patients with all degrees of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤35 percent were randomized to placebo or enalapril and followed for up to 55 months (SOLVD-Treatment). Use of enalapril was associated with an 11 percent reduction in all-cause mortality and a 30 percent reduction in hospitalization for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Diseases that excluded patients from enrollment in the study included severe stable angina (&gt;2 attacks/day), hemodynamically significant valvular or outflow tract obstruction, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (creatinine &gt;2.5 mg/dL), cerebral vascular disease (e.g., significant <span class="product-label-link" type="condition" conceptid="4153380" conceptname="Disorder of carotid artery">carotid artery disease</span>), advanced pulmonary disease, malignancies, active <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="312334" conceptname="Constrictive pericarditis">constrictive pericarditis</span>. The mortality benefit associated with enalapril does not appear to depend upon digitalis being present.</p>
<p>A second multicenter trial used the SOLVD protocol for study of asymptomatic or minimally symptomatic patients. SOLVD-Prevention patients, who had left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤35% and no history of symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, were randomized to placebo (n=2117) or enalapril (n=2111) and followed for up to 5 years. The majority of patients in the SOLVD-Prevention trial had a history of <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>. A history of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> was present in 80 percent of patients, current <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span> in 34 percent, and a history of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> in 37 percent. No statistically significant mortality effect was demonstrated in this population. Enalapril-treated subjects had 32% fewer first hospitalizations for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, and 32% fewer total <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> hospitalizations. Compared to placebo, 32 percent fewer patients receiving enalapril developed symptoms of overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. Hospitalizations for cardiovascular reasons were also reduced. There was an insignificant reduction in hospitalizations for any cause in the enalapril treatment group (for enalapril vs. placebo, respectively, 1166 vs. 1201 first hospitalizations, 2649 vs. 2840 total hospitalizations), although the study was not powered to look for such an effect.</p>
<p>The SOLVD-Prevention trial was not designed to determine whether treatment of asymptomatic patients with low <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> would be superior, with respect to preventing hospitalization, to closer follow-up and use of enalapril at the earliest sign of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. However, under the conditions of follow-up in the SOLVD-Prevention trial (every 4 months at the study clinic; personal physician as needed), 68% of patients on placebo who were hospitalized for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> had no prior symptoms recorded which would have signaled initiation of treatment.</p>
<p>The SOLVD-Prevention trial was also not designed to show whether enalapril modified the progression of underlying heart disease.</p>
<p>In another multicenter, placebo-controlled trial (CONSENSUS) limited to patients with NYHA Class IV <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and radiographic evidence of <span class="product-label-link" type="condition" conceptid="314658" conceptname="Cardiomegaly">cardiomegaly</span>, use of enalapril was associated with improved survival. The results are shown in the following table.</p>
<table width="100%">
<col width="33%">
<col width="30%">
<col width="30%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="3"><p class="First"><span class="Bold">CONCENSUS Survival Rates</span></p></td></tr>
<tr>
<td></td>
<td align="center" colspan="2"><p class="First"><span class="Bold">SURVIVAL (%)</span></p></td>
</tr>
<tr>
<td></td>
<td align="center"><p class="First"><span class="Bold">Â Â Â Â Â Â Â Â Â Â SixÂ MonthsÂ Â Â Â Â Â Â Â Â Â </span></p></td>
<td align="center"><p class="First"><span class="Bold">Â Â Â Â Â Â Â Â Â Â OneÂ YearÂ Â Â Â Â Â Â Â Â Â </span></p></td>
</tr>
<tr>
<td><p class="First">VASOTEC<span class="Sup">Â®</span>Â (n=127)Â Â Â Â Â Â Â Â Â Â </p></td>
<td align="center"><p class="First">74</p></td>
<td align="center"><p class="First">64</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Placebo (n=126)</p></td>
<td class="Botrule" align="center"><p class="First">56</p></td>
<td class="Botrule" align="center"><p class="First">48</p></td>
</tr>
</tbody>
</table>
<p>In both CONSENSUS and SOLVD-Treatment trials, patients were also usually receiving digitalis, diuretics or both.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_d100ab6f-bcd3-4ce3-b899-d04e9f3474c7"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">EPANED is supplied as a kit. </p>
<p>NDCÂ 52652-1001-1 </p>
<dl>
<dt>â€¢</dt>
<dd>One bottle containing EPANED Powder (150 mg enalapril maleate) for Oral Solution in an HDPE bottle with child-resistant cap to provide 1 mg/mL final concentration after reconstitution.</dd>
<dt>â€¢</dt>
<dd>One bottle containing 150 mL of Ora-Sweet SF provided as the diluent for reconstitution.</dd>
</dl>
<p>Store at 25Â°C (77Â°F); excursions permitted to 15-30Â°C (59-86Â°F) [see USP Controlled Room Temperature]. </p>
<p>Do not freeze.</p>
<p>Keep container tightly closed.</p>
<p>Protect from moisture.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_b6d4bb29-f33f-4658-a3d2-b5440dd0fb1d"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Pregnancy</span></dd>
</dl>
<p class="First">Tell female patients of childbearing age about the consequences of exposure to EPANED during pregnancy. Discuss treatment options with women planning to become pregnant. Patients should be asked to report pregnancies to their physicians as soon as possible.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></span></dd>
</dl>
<p><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>, including <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, may occur at any time during treatment with angiotensin-converting enzyme inhibitors, including enalapril. Advise patients to report immediately any signs or symptoms suggesting <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (<span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">swelling of face</span>, extremities, eyes, lips, or tongue, or difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></dd>
</dl>
<p>Caution patients to report <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, especially during the first few days of therapy. If actual <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurs, tell patients to discontinue the drug until they have consulted with the prescribing physician.</p>
<p>Tell patients that excessive perspiration and <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span> may lead to an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> because of reduction in fluid volume. Other causes of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span> such as <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may also lead to a <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span>; advise patients to consult with their physician.</p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></dd>
</dl>
<p>Tell patients not to use salt substitutes containing potassium without consulting their physician.</p>
<p>EPANED is a trademark of Silvergate Pharmaceuticals, Inc.</p>
<p>Ora-Sweet SF is a registered trademark of Paddock Laboratories, Inc.</p>
<p>VASOTEC is a registered trademark of Valeant International Bermuda.</p>
<p>Manufactured For: <br>Silvergate Pharmaceuticals, Inc.<br>6251 Greenwood Plaza Blvd., Suite 101<br>Greenwood Village, CO 80111</p>
<p>U. S. Patent 8568747; 8778366</p>
<p>EN-1408</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_52d22b6e-2c51-4c23-a6a4-fe4f7154a79d"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - CARTON</h1>
<div class="Figure">
<a name="id-980765388"></a><img alt="Principal Display Panel - Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94c9a9d6-957f-4667-8f09-509e99bac777&amp;name=image-02.jpg"><p class="MultiMediaCaption">Carton</p>
</div>
<p class="First">NDC 52652-1001-1</p>
<p><span class="Bold">Kit for Preparation of</span></p>
<p><span class="Bold">Epaned<span class="Sup">Â®</span></span><br><span class="Bold">(Enalapril Maleate</span><br><span class="Bold">Powder for Oral Solution)</span><br>1 mg/mL</p>
<p>When reconstituted, each mL contains:<br><span class="Bold">Enalapril maleate 1 mg</span><br>150 mL (when reconstituted)</p>
<p><span class="Bold">CONTAINS:</span></p>
<p>I. 1 bottle containing 150 mg Enalapril Maleate Powder<br>for Oral Solution</p>
<p>II. 1 bottle containing 150 mL Ora-Sweet<span class="Sup">Â®</span> SF provided as<br>a diluent for reconstitution</p>
<p>Store at controlled room temperature, 15-30Â°C (59-86Â°F).<br>[See USP Controlled Room Temperature] Do not freeze.</p>
<p>DISCARD 60 DAYS AFTER RECONSTITUTION.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Epaned<span class="Sup">Â®</span> Powder for Oral Solution Kit</span></p>
<p><span class="Bold">Directions for mixing: </span>Firmly tap the Epaned Powder for Oral Solution bottle on a hard<br>surface 5 times. Add approximately one-half (75 mL) of the Ora-Sweet<span class="Sup">Â®</span> SF diluent to the<br>Epaned Powder for Oral Solution bottle. <span class="Bold">Shake well for 30 seconds</span>. Reopen. Add the<br>remainder of the Ora-Sweet SF diluent to the Epaned Powder for Oral Solution bottle<br>and <span class="Bold">shake well for an additional 30 seconds</span>. Calculate 60 days from the date of<br>reconstitution. Write this date as the discard date on the front label. Affix a â€œDo Not Use<br>Afterâ€? or a â€œDiscard Afterâ€? label with the calculated date added to the reconstituted<br>Epaned bottle. Reconstitution results in 150 mL of a 1 mg/mL Epaned Oral Solution.</p>
<p><span class="Bold">Dosage:</span> See Package Insert for dosing information.</p>
<p>NDC 52652-1001-1</p>
<p><span class="Bold">Epaned<span class="Sup">Â®</span></span><br><span class="Bold">(Enalapril Maleate</span><br><span class="Bold">Powder for Oral Solution)</span><br>1 mg/mL</p>
<p><span class="Bold">When reconstituted, each mL contains:</span><br><span class="Bold">Enalapril maleate 1 mg</span><br>150 mL (when reconstituted)</p>
<p>Manufactured for:<br>Silvergate Pharmaceuticals, Inc.<br>6251 Greenwood Plaza Blvd, Suite 101<br>Greenwood Village, CO 80111</p>
<p>Silvergate, the Silvergate logo, and Epaned are trademarks<br>of Silvergate Pharmaceuticals, Inc. All other registered<br>trademarks are the property of their respective owners.<br>(08/14)</p>
<p>Silvergate Pharmaceuticals, Inc.</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Epaned<span class="Sup">Â®</span> Powder for Oral Solution Kit contains:</span></p>
<p>I. 1 bottle containing 150 mg Enalapril Maleate Powder for<br>Oral Solution</p>
<p>II. 1 bottle containing 150 mL Ora-Sweet<span class="Sup">Â®</span> SF provided as a diluent<br>for reconstitution</p>
<p>Dosage: See Package Insert for dosing information.</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>EPANEDÂ 		
					</strong><br><span class="contentTableReg">enalapril maleate kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52652-1001</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52652-1001-1</td>
<td class="formItem">1  in 1 CARTON; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">PartÂ #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 BOTTLE </td>
<td class="formItem">150Â mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 BOTTLE </td>
<td class="formItem">150Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>EPANEDÂ 		
					</strong><br><span class="contentTableReg">enalapril maleate powder, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENALAPRIL MALEATE</strong> (ENALAPRILAT ANHYDROUS) </td>
<td class="formItem">ENALAPRIL MALEATE</td>
<td class="formItem">1Â mg Â inÂ 1Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">150 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204308</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>ORA-SWEET SFÂ 		
					</strong><br><span class="contentTableReg">water, glycerin, sorbitol, sodium saccharin, xanthan gum syrup</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt"></tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SORBITOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>XANTHAN GUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CITRIC ACID MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CITRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POTASSIUM SORBATE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">150 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204308</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA204308</td>
<td class="formItem">08/22/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Silvergate Pharmaceuticals, Inc.
							(011248265)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Medichem, S.A.</td>
<td class="formItem"></td>
<td class="formItem">464043381</td>
<td class="formItem">API MANUFACTURE(52652-1001)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">KP Pharmaceutical Technology, Inc.</td>
<td class="formItem"></td>
<td class="formItem">089531958</td>
<td class="formItem">MANUFACTURE(52652-1001)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">SGS Life Science Services</td>
<td class="formItem"></td>
<td class="formItem">062491980</td>
<td class="formItem">ANALYSIS(52652-1001)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Paddock Laboratories, LLC</td>
<td class="formItem"></td>
<td class="formItem">967694121</td>
<td class="formItem">MANUFACTURE(52652-1001)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>560dde90-e873-4687-8f68-c2b0ccaefc58</div>
<div>Set id: 94c9a9d6-957f-4667-8f09-509e99bac777</div>
<div>Version: 3</div>
<div>Effective Time: 20150112</div>
</div>
</div>Â <div class="DistributorName">Silvergate Pharmaceuticals, Inc.</div></p>
</body></html>
